Late pregnancy complications in study participants available for primary outcome analysis, according to treatment arm
| . | Nadroparin and medical surveillance (n = 63) . | Medical surveillance alone (n = 65) . | Absolute risk difference (95% CI) . | P . |
|---|---|---|---|---|
| Recurrent pregnancy complications, n (%) | 13 (20.6) | 12 (18.5) | 2.2 (−11.6 to 16.0) | .76 |
| Preeclampsia | 5 (7.9) | 3 (4.6) | 3.3 (−5.9 to 13.1) | .44 |
| Eclampsia | 0 | 0 | NA | NA |
| HELLP syndrome | 1 (1.6) | 0 | 1.6 (−4.2 to 8.5) | .49 |
| Intrauterine fetal death | 2 (3.2) | 1 (1.5) | 1.6 (−5.4 to 9.4) | .62 |
| FGR | 5 (7.9) | 7 (10.8) | −2.8 (−13.6 to 8.0) | .58 |
| Placental abruption | 0 | 1 (1.5) | −1.5 (−8.2 to 4.3) | 1.0 |
| . | Nadroparin and medical surveillance (n = 63) . | Medical surveillance alone (n = 65) . | Absolute risk difference (95% CI) . | P . |
|---|---|---|---|---|
| Recurrent pregnancy complications, n (%) | 13 (20.6) | 12 (18.5) | 2.2 (−11.6 to 16.0) | .76 |
| Preeclampsia | 5 (7.9) | 3 (4.6) | 3.3 (−5.9 to 13.1) | .44 |
| Eclampsia | 0 | 0 | NA | NA |
| HELLP syndrome | 1 (1.6) | 0 | 1.6 (−4.2 to 8.5) | .49 |
| Intrauterine fetal death | 2 (3.2) | 1 (1.5) | 1.6 (−5.4 to 9.4) | .62 |
| FGR | 5 (7.9) | 7 (10.8) | −2.8 (−13.6 to 8.0) | .58 |
| Placental abruption | 0 | 1 (1.5) | −1.5 (−8.2 to 4.3) | 1.0 |
NA indicates not applicable.